These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3615930)

  • 1. [Hepatic metabolism of antipyrine in patients with acute pancreatitis].
    Lukaszyk A
    Przegl Lek; 1987; 44(2):273-6. PubMed ID: 3615930
    [No Abstract]   [Full Text] [Related]  

  • 2. [Monooxigenase activity in liver diseases (study based on data of antipyrine metabolism)].
    Loginov AS; Bendikov EA; Kel'nia ZhA; Petrakov AV
    Ter Arkh; 1987; 59(2):84-9. PubMed ID: 3576485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impairment of hepatic drug metabolism in patients with Budd-Chiari syndrome.
    Narang AP; Datta DV; Mathur VS
    Indian J Med Res; 1982 Apr; 75():567-73. PubMed ID: 7106896
    [No Abstract]   [Full Text] [Related]  

  • 5. Liver failure and drug metabolism.
    Andreasen PB; Ranek L
    Scand J Gastroenterol; 1975; 10(3):293-7. PubMed ID: 1138332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of inflammation and cholestasis on the metabolic function of the liver].
    Kogan AS; Nepomniashchikh VA
    Khirurgiia (Mosk); 1987 Feb; (2):79-81. PubMed ID: 3560745
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pharmacometabolic capacity of the liver and the effect of pancreozymin in chronic hepatitis, chronic pancreatitis and diabetes mellitus].
    Geller LI; Griaznova MV; Bulgakova OS; Kozlova ZP
    Ter Arkh; 1982; 54(2):67-9. PubMed ID: 7071776
    [No Abstract]   [Full Text] [Related]  

  • 8. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination].
    Soto Alvarez J; Alsar Ortiz MJ
    Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipyrine kinetics following tetanus vaccination.
    Descotes J; Simonet R; Evreux JC
    Int J Clin Pharmacol Ther Toxicol; 1986 Nov; 24(11):625-6. PubMed ID: 3793297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hepatic drug metabolism in patients with intrahepatic cholestasis (author's transl)].
    Deschamps JP; Miguet JP; Vuitton D; Joanne C; Allemand H; Carayon P; Bechtel P; Gisselbrecht H
    Gastroenterol Clin Biol; 1979 May; 3(5):439-45. PubMed ID: 535711
    [No Abstract]   [Full Text] [Related]  

  • 11. Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease.
    Krausz Y; Zylber-Katz E; Levy M
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):253-7. PubMed ID: 7450926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (Catergen) in chronic alcoholic liver disease.
    Pár A; Horváth T; Beró T; Kádas I; Pakodi F; Jávor T
    Acta Physiol Hung; 1984; 64(3-4):449-54. PubMed ID: 6152369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of phenazone as an indicator of the metabolic capacity of the liver in patients with hyperthyroidism].
    Orzechowska-Juzwenko K; Bolanowski M; Gruszka S; Szymczak J
    Pol Tyg Lek; 1983 May 16-23; 38(20-21):643-5. PubMed ID: 6647129
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chronic renal failure as a factor modifying drug metabolism in the body].
    Orzechowska-Juzwenko K; Milejski P; Kazimierczak K; Szewczyk Z
    Pol Tyg Lek; 1986 Dec 22-29; 41(51-52):1638-40. PubMed ID: 3588383
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effect of acute biliary pancreatitis on liver metabolism of phenazone].
    Hartleb M; Nowak A; Nowakowska-Duława E; Mańczyk I; Becker A; Kacperek T
    Pol Arch Med Wewn; 1990 Mar; 83(3):104-10. PubMed ID: 2216933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolism of antipyrine in patients with chronic renal failure.
    Lichter M; Black M; Arias IM
    J Pharmacol Exp Ther; 1973 Dec; 187(3):612-9. PubMed ID: 4588969
    [No Abstract]   [Full Text] [Related]  

  • 17. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment of drug elimination in patients with liver disease.
    Narang AP; Datta DV; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of age on antipyrine metabolism in patients with gastric cancer.
    Higuchi T; Nakamura T; Uchino H
    J Natl Cancer Inst; 1980 Nov; 65(5):897-900. PubMed ID: 6933259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of hepatic drug metabolism in female patients with congestive cardiac failure.
    Rissam HS; Nair CR; Anand IS; Madappa C; Wahi PL
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):602-4. PubMed ID: 6668098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.